The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 15th Annual PD Therapeutics Conference is scheduled to be held on October 19, 2023, in New York.
Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
Thank you for your tremendous enthusiasm for this year's event. Registration has reached its maximum capacity. We will shortly inform those who had joined the waitlist about their potential to attend.
For any questions, please contact firstname.lastname@example.org.
Jamie Adams, MD | University of Rochester
Tien Dam, MD | Biogen
Vicky DiBiaso, PhD | Sanofi
Jamie Eberling, PhD | The Michael J. Fox Foundation
Tanya Fischer, MD, PhD | Biohaven
Alison Handler, PharmD, RPh | Novartis
Karl Kieburtz, MD, MPH | University of Rochester
Catherine Kopil, PhD | The Michael J. Fox Foundation
Ken Marek, MD | Institute for Neurodegenerative Disorders
Soania Mathur, MD | MJFF Patient Council Member
Kalpana Merchant, PhD | TransThera Consulting
Tom Montine, MD, PhD | Stanford University
Karoly Nikolich, PhD | Alkahest Inc.
Gennaro Pagano, MD, PhD | Roche
Niels Plath, PhD | Muna Therapeutics
Kathleen Poston, MD, MS | Stanford University
Gary Rafaloff | MJFF Patient Council Member
Andrew Singleton, PhD | National Institutes of Health
David Stone, PhD | Cerevel Therapeutics
Bill Shrader, PhD | AcureX
Paul Thompson, PhD | Mission Therapeutics
Kendall Van Keuren-Jensen, PhD | Translational Genomics Research Institute
Path to Prevention (P2P) Trial: Study Design and Status Update
Tanya Simuni, MD | Northwestern University
A Machine Learning Contest to Automatically Detect Freezing of Gait: Results and Insights
Jeff Hausdorff, PhD | Tel Aviv Medical Center
Aligning with Regulators to Advance Patient-Reported Outcome Assessments that are Fit-for-Purpose in Early-Stage Parkinson’s Disease Clinical Trials
Diane Stephenson, PhD | Critical Path Institute
The London-Dhaka Project – the Prevalence and Assessment of Cognitive Impairment in Parkinson’s Disease
Alastair Noyce, MSc, MRCP, PhD, FHEA | Queen Mary University of London
Hit-to-Lead STING Inhibitor Small Molecule Development for Parkinson’s Disease
,John Streiff, PhD | AeroNeph Therapeutics
The Lysosomal Polyamine Transporter ATP13A2, an Emerging Drug Target for Parkinson’s Disease
Peter Vangheluwe, PhD | KU Leuven
MJFF Tools Overview
Nicole Polinski, PhD | MJFF
The National Plan to End Parkinson’s Act
Dustin Watson | MJFF
The 15th annual Parkinson's Disease Therapeutics Conference is made possible by the support of our generous sponsors:
Interested in Sponsorship Opportunities?
View our sponsorship opportunities menu to support this year's conference.
Contact our Research Alliances team at email@example.com with questions.